Document is current
Any future updates will be listed below
-
Authors
Amrani, Nadia
Gao, Xin D.
Liu, Pengpeng
Edraki, Alireza
Mir, Aamir
Ibraheim, Raed
Gupta, Ankit
Sasaki, Kanae E.
Wu, Tong
Donohoue, Paul D.
Settle, Alexander H.
Lied, Alexandra M.
McGovern, Kyle
Fuller, Chris K.
Cameron, Peter
Fazzio, Thomas G.
Zhu, Lihua Julie
Wolfe, Scot A.
Sontheimer, Erik J. https://orcid.org/0000-0002-0881-0310
-
Funding
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (GM115911)
Intellia Therapeutics (N/A)
- License Information
-
More Information
Article History
Received: 9 May 2018
Accepted: 17 November 2018
First Online: 5 December 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: E.J.S. is a co-founder and scientific advisor of Intellia Therapeutics. P.D.D, A.H.S, A.M.L, K.M, C.K.F, and P.C are current or former employees of Caribou Biosciences, Inc., a company that develops and commercializes genome engineering technologies, and such individuals may own shares or stock options in Caribou Biosciences. SITE-Seq is a trademark of Caribou Biosciences, Inc. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
